Matches in SemOpenAlex for { <https://semopenalex.org/work/W4312781312> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W4312781312 abstract "Biologics are available for the treatment of severe allergic asthma (SAA) with blood eosinophil count (BEC)≥0.3x10<sup>9</sup>/L. Several of them showed also benefits on nasal polyps (NP), one of the most frequent comorbidities of severe asthma but comparative studies on their effectiveness in the association SAA-NP are currently lacking. The aim of the study was to compare the effectiveness of benralizumab, mepolizumab and omalizumab in patients with SAA-NP in real-life settings. A retrospective, observational, multicenter real-life study was realized including patients with SAA-NP treated by benralizumab, mepolizumab or omalizumab for 6 months. We analyzed the nasal and respiratory symptoms, the number of asthma attacks and salbutamol use/week, acute sinusitis and severe exacerbations rates, the asthma control score, the lung function parameters, the NP endoscopic score, the sinus imaging, and the BEC 6 months before and after treatment. Seventy-two patients with SAA-NP were included: 16 treated by benralizumab, 21 by mepolizumab and 35 by omalizumab. After 6 months of treatment, almost all studied parameters were improved (except sinus imaging) with a greater effect of the omalizumab on the nasal pruritus (p=0.001) and more benefits of the benralizumab on asthma control, asthma attacks per week, and lung function (all p<0.05). Benralizumab and mepolizumab were more effective to improve the NP endoscopic score and the BEC (both p<0.001). The three biologics showed comparative effectiveness by improving asthma and nasal disease outcomes in patients with SAA-NP. Several differences have been found that should be confirmed by future largest studies." @default.
- W4312781312 created "2023-01-05" @default.
- W4312781312 creator A5002669376 @default.
- W4312781312 creator A5009106496 @default.
- W4312781312 creator A5009743002 @default.
- W4312781312 creator A5026611727 @default.
- W4312781312 creator A5030187322 @default.
- W4312781312 creator A5040415255 @default.
- W4312781312 creator A5053277429 @default.
- W4312781312 creator A5078995290 @default.
- W4312781312 creator A5080483711 @default.
- W4312781312 creator A5086420380 @default.
- W4312781312 creator A5090023985 @default.
- W4312781312 date "2022-09-04" @default.
- W4312781312 modified "2023-09-28" @default.
- W4312781312 title "Real-life comparative study on the effectiveness of benralizumab, mepolizumab and omalizumab in severe allergic asthma associated with nasal polyps" @default.
- W4312781312 doi "https://doi.org/10.1183/13993003.congress-2022.758" @default.
- W4312781312 hasPublicationYear "2022" @default.
- W4312781312 type Work @default.
- W4312781312 citedByCount "1" @default.
- W4312781312 countsByYear W43127813122023 @default.
- W4312781312 crossrefType "proceedings-article" @default.
- W4312781312 hasAuthorship W4312781312A5002669376 @default.
- W4312781312 hasAuthorship W4312781312A5009106496 @default.
- W4312781312 hasAuthorship W4312781312A5009743002 @default.
- W4312781312 hasAuthorship W4312781312A5026611727 @default.
- W4312781312 hasAuthorship W4312781312A5030187322 @default.
- W4312781312 hasAuthorship W4312781312A5040415255 @default.
- W4312781312 hasAuthorship W4312781312A5053277429 @default.
- W4312781312 hasAuthorship W4312781312A5078995290 @default.
- W4312781312 hasAuthorship W4312781312A5080483711 @default.
- W4312781312 hasAuthorship W4312781312A5086420380 @default.
- W4312781312 hasAuthorship W4312781312A5090023985 @default.
- W4312781312 hasConcept C126322002 @default.
- W4312781312 hasConcept C141105273 @default.
- W4312781312 hasConcept C159654299 @default.
- W4312781312 hasConcept C203014093 @default.
- W4312781312 hasConcept C2776042228 @default.
- W4312781312 hasConcept C2777037409 @default.
- W4312781312 hasConcept C2777768476 @default.
- W4312781312 hasConcept C2777832160 @default.
- W4312781312 hasConcept C2778564945 @default.
- W4312781312 hasConcept C2779185760 @default.
- W4312781312 hasConcept C2781390199 @default.
- W4312781312 hasConcept C71924100 @default.
- W4312781312 hasConcept C90924648 @default.
- W4312781312 hasConceptScore W4312781312C126322002 @default.
- W4312781312 hasConceptScore W4312781312C141105273 @default.
- W4312781312 hasConceptScore W4312781312C159654299 @default.
- W4312781312 hasConceptScore W4312781312C203014093 @default.
- W4312781312 hasConceptScore W4312781312C2776042228 @default.
- W4312781312 hasConceptScore W4312781312C2777037409 @default.
- W4312781312 hasConceptScore W4312781312C2777768476 @default.
- W4312781312 hasConceptScore W4312781312C2777832160 @default.
- W4312781312 hasConceptScore W4312781312C2778564945 @default.
- W4312781312 hasConceptScore W4312781312C2779185760 @default.
- W4312781312 hasConceptScore W4312781312C2781390199 @default.
- W4312781312 hasConceptScore W4312781312C71924100 @default.
- W4312781312 hasConceptScore W4312781312C90924648 @default.
- W4312781312 hasLocation W43127813121 @default.
- W4312781312 hasOpenAccess W4312781312 @default.
- W4312781312 hasPrimaryLocation W43127813121 @default.
- W4312781312 hasRelatedWork W2185828908 @default.
- W4312781312 hasRelatedWork W2593223898 @default.
- W4312781312 hasRelatedWork W2984771423 @default.
- W4312781312 hasRelatedWork W3016093612 @default.
- W4312781312 hasRelatedWork W3119831431 @default.
- W4312781312 hasRelatedWork W4223935457 @default.
- W4312781312 hasRelatedWork W4287582765 @default.
- W4312781312 hasRelatedWork W4312781312 @default.
- W4312781312 hasRelatedWork W4320492299 @default.
- W4312781312 hasRelatedWork W4377011870 @default.
- W4312781312 isParatext "false" @default.
- W4312781312 isRetracted "false" @default.
- W4312781312 workType "article" @default.